ClinicalTrials.gg
CompletedNCT05635708Updated Oct 30, 2026

A Study of Tislelizumab in Combination With Investigational Agents in Participants With Non-Small Cell Lung Cancer

A Phase 2 interventional study of Tislelizumab and BGB-A445 in Non-small Cell Lung Cancer and Metastatic Non-small Cell Lung Cancer, sponsored by BeiGene. Completed at 61 sites in 15 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-10-30.

Sponsored by BeiGene · Phase 2, Interventional, and Treatment

Updated Oct 30, 2026Now CompletedStart date moved+2 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
418
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 41 studies testing tislelizumab in Carcinoma, Non-Small-Cell Lung — 20 open to participants now, 22 under way, 2 of them phase 3. tislelizumab · Carcinoma, Non-Small-Cell Lung.

Enrollment
4th of 41
418 · median 39
Started
2023
with 5 others
Phase 2
26 of 41
17 open now
Registered
19th of 41
by date
Lead sponsor
10 of 41
BeiGene

Among the 41 studies testing tislelizumab in Carcinoma, Non-Small-Cell Lung, this one is the 4th largest by enrollment, is one of 6 that started in 2023, is one of 26 in phase 2, and was the 19th registered.

Carcinoma, Non-Small-Cell Lung

7,628 studies on the registry are indexed under Carcinoma, Non-Small-Cell Lung; 1,838 are open to participants now.

Browse Carcinoma, Non-Small-Cell Lung studies →

Open to participants now

20 of the 41 studies testing tislelizumab in Carcinoma, Non-Small-Cell Lung are open now, in 1 country. Recruiting first, the newest first:

15 more — sign in →

By country, each count listing its studies:

All 20 open studies →

About tislelizumab

tislelizumab: first FDA approval 2024 (TEVIMBRA), first EMA approval 2023. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 1,325 Carcinoma, Non-Small-Cell Lung studies recruiting now, 988 (75%) set no upper age limit and 224 (17%) stop at 75 or younger; 34 take children under 18; 40 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 41 studies testing tislelizumab in Carcinoma, Non-Small-Cell Lung, or all of them as a file.
02

Study summary

The purpose of this study is to assess the antitumor activity, safety, and tolerability of tislelizumab plus investigational agent(s) with or without chemotherapy. This study is structured as a master protocol with separate sub- studies. Sub-study 1 includes participants with non-small cell lung cancer (NSCLC) with high programmed cell death protein ligand-1 (PD-L1) expression (≥ 50%), and Sub-study 2 includes participants with NSCLC with low or negative (PD-L1) expression (\< 50%).

03

Conditions studied

  • Non-small Cell Lung Cancer
  • Metastatic Non-small Cell Lung Cancer

Keywords

  • Non-small Cell Lung Cancer
  • NSCLC
  • programmed cell death protein-1
  • PD-L1 Low Tumors
  • PD-L1 Negative Tumors
  • Metastatic Non-Small Cell Lung Cancer
  • PD-L1 High Tumors
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Eligibility criteria

Key Inclusion Criteria:

  1. or cytologically confirmed non-small cell lung cancer (NSCLC), including nonsquamous or squamous subtypes, that is either locally advanced or recurrent and not eligible for curative surgery and/or definitive chemoradiotherapy, or NSCLC.
  2. No prior systemic therapy administered as the primary treatment for metastatic NSCLC. Prior or neoadjuvant chemotherapy, definitive chemoradiation, or adjuvant radiotherapy for locally advanced disease is permitted, provided the last dose of chemotherapy and/or radiotherapy occurred at least 6 months prior to randomization/enrollment.
  3. Tumor programmed death-ligand 1 () expression must be evaluable, as determined by a local or central laboratory using or a fresh biopsy. Participants with unknown PD-L1 expression are not eligible.
  4. At least one , as defined by (RECIST) version 1.1.
  5. (ECOG) Performance Status of 0 or 1.

Key Exclusion Criteria:

  1. Diagnosis of mixed small cell lung cancer.
  2. Known genomic alterations for which effective targeted therapies are available according to local standard of care, including but not limited to:

    • Epidermal growth factor receptor (EGFR) mutations
    • Anaplastic lymphoma kinase (ALK) rearrangements
    • B-Raf proto-oncogene (BRAF) mutations
    • Rearranged during transfection (RET) fusions
    • c-ros oncogene 1 (ROS1) rearrangements
  3. Participants with nonsquamous NSCLC and unknown EGFR mutation status must undergo local testing. Those found to have EGFR-sensitizing mutations will be excluded.
  4. Prior treatment with immune-based therapies that target immune checkpoint pathways, including:

    • PD-1 (programmed cell death protein 1) inhibitors
    • PD-L1 (programmed death-ligand 1) inhibitors
    • PD-L2 (programmed death-ligand 2) inhibitors
    • TIGIT (T cell immunoreceptor with Ig and ITIM domains) inhibitors
    • LAG-3 (lymphocyte activation gene 3) inhibitors
  5. Participants previously treated with these agents in a neoadjuvant, adjuvant, or consolidation setting may be eligible if a treatment-free interval of at least 6 months has elapsed since the last dose and radiologic evidence of recurrence is present.
  6. Use of Chinese herbal medicines or Chinese patent medicines intended for cancer control within 14 days prior to randomization/enrollment.
  7. Presence of active , untreated or uncontrolled , or active disease.

Note: Additional protocol-defined and sub-study-specific criteria may apply.

Terms in these criteria, in plain language(11)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

Adjuvant and neoadjuvant

Neoadjuvant treatment is given before the main treatment (usually surgery), often to shrink a tumor. Adjuvant treatment is given after it, to lower the chance of the cancer coming back.

PD-1, PD-L1 and checkpoint inhibitors

PD-1, PD-L1 and CTLA-4 are proteins that act as brakes on the immune system. Checkpoint inhibitors, such as pembrolizumab or nivolumab, block them so the immune system can attack a cancer.

PD-L1 can also be measured in a tumor sample. Some scores count stained tumor cells only (TPS); others also count certain immune cells (CPS). The study names the score and the minimum it uses.

Biopsy and archival tissue

A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.

Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.

Measurable disease

The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.

The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.

RECIST

The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.

“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Leptomeningeal disease

Cancer that has spread to the leptomeninges, the thin layers covering the brain and spinal cord, and the fluid between them. It is not the same as brain metastases.

Criteria often treat it separately, and many studies leave it out even where treated brain metastases are allowed.

Brain metastases

Cancer deposits in the brain from a cancer that started elsewhere in the body (CNS metastases include the spinal cord).

Studies differ: some leave out any brain metastases, some accept ones treated and stable for some weeks. Check what this study allows.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
418 participants (actual)

Study arms

  • Experimental
    Sub-study 1: Arm 1A

    Tislelizumab + BGB-A445

  • Experimental
    Sub-study 1: Arm 2A

    Tislelizumab + LBL-007

    Drug: Tislelizumab · Drug: LBL-007

  • Experimental
    Sub-study 1: Arm 3A

    Tislelizumab + BGB-15025

    Drug: Tislelizumab · Drug: BGB-15025

  • Active comparator
    Sub-study 1: Reference Arm Tislelizumab alone

    Tislelizumab alone

    Drug: Tislelizumab

  • Experimental
    Sub-study 2: Arm 1B

    Tislelizumab + investigator's choice of histology-appropriate chemotherapy + BGB-A445

    Drug: Tislelizumab · Drug: BGB-A445 · Drug: Carboplatin · Drug: Cisplatin · Drug: pemetrexed · Drug: Paclitaxel · Drug: Nab paclitaxel

  • Experimental
    Sub-study 2: Arm 2B

    Tislelizumab + investigator's choice of histology-appropriate chemotherapy + LBL-007

    Drug: Tislelizumab · Drug: LBL-007 · Drug: Carboplatin · Drug: Cisplatin · Drug: pemetrexed · Drug: Paclitaxel · Drug: Nab paclitaxel

  • Experimental
    Sub-study 2: Arm 3B

    Tislelizumab + investigator's choice of histology-appropriate chemotherapy + BGB-15025

    Drug: Tislelizumab · Drug: Carboplatin · Drug: Cisplatin · Drug: pemetrexed · Drug: Paclitaxel · Drug: Nab paclitaxel · Drug: BGB-15025

  • Active comparator
    Sub-study 2: Reference Arm

    Tislelizumab + investigator's choice of histology-appropriate chemotherapy

    Drug: Tislelizumab · Drug: Carboplatin · Drug: Cisplatin · Drug: pemetrexed · Drug: Paclitaxel · Drug: Nab paclitaxel

Interventions

  • Administered by intravenous infusion

  • DrugBGB-A445

    Administered by intravenous infusion

  • Administered by intravenous infusion

  • Investigator's choice; administered by intravenous infusion

  • Investigator's choice; administered by intravenous infusion

  • Investigator's choice; administered by intravenous infusion

  • Investigator's choice; administered by intravenous infusion

  • Investigator's choice; administered by intravenous infusion

  • DrugBGB-15025

    Administered Orally

06

What researchers measure

Primary outcomes

  1. Confirmed overall response rate (ORR)

    ORR is defined as the percentage of participants with partial or complete response, as assessed by the investigator using the Response Evaluation Criteria in Solid Tumors (RECIST) Version (v)1.1

    Time frame: Up to 6 months

Secondary outcomes

  1. Progression-free survival (PFS)

    PFS is defined as the time from date of randomization, or the first dose for safety lead-in participants , until first documentation of progression or death, whichever comes first, as assessed by the investigator using RECIST v1.

    Time frame: Up to 1 year

  2. Duration of Response (DOR)

    DOR is defined as the time from the first determination of a confirmed response per RECIST v1.1 until the first documentation of progression or death, whichever comes first as assessed by the investigator

    Time frame: Up to 1 year

  3. Clinical Benefit Rate (CBR)

    CBR is defined as the percentage of participants with a best overall response of a complete response, partial response, or durable stable disease, as assessed by the investigator using RECIST v1.1

    Time frame: Up to 6 months

  4. Disease Control Rate (DCR)

    DCR is defined as the percentage of participants with a best overall response of complete response, partial response, or stable disease, as assessed by the investigator using RECIST v1.1

    Time frame: Up to 6 months

  5. Number of participants with adverse events (AEs)

    Number of participants with treatment-emergent adverse events (TEAEs) and serious adverse events (SAEs), including laboratory values, vital signs, physical examination findings, and electrocardiogram results.

    Time frame: From the first dose of study drug(s) to 90 days after initiation of new anticancer therapy, death, withdrawal of consent, or loss to follow-up, whichever occurs first, up to approximately 2 years

07

Study locations

61 sites
  • Valkyrie Clinical Trials
    Los Angeles, California 90067-2011, United States
  • Massachusetts General Hospital
    Boston, Massachusetts 02114, United States
  • Memorial Sloan Kettering Cancer Center Mskcc
    New York, New York 10065-6800, United States
  • Providence Portland Medical Center
    Portland, Oregon 97213-2933, United States
  • The University of Texas Md Anderson Cancer Center
    Houston, Texas 77030-4009, United States
  • Blacktown Cancer and Haematology Centre
    Blacktown, New South Wales NSW 2148, Australia
  • Chris Obrien Lifehouse
    Camperdown, New South Wales NSW 2050, Australia
  • Northern Beaches Hospital
    Frenchs Forest, New South Wales NSW 2086, Australia
  • Port Macquarie Base Hospital
    Port Macquarie, New South Wales NSW 2444, Australia
  • One Clinical Research
    Nedlands, Western Australia WA 6009, Australia
  • St John of God Health Care
    Subiaco, Western Australia WA 6008, Australia
  • Hospital de Amor Barretos
    Barretos, 14784-400, Brazil
  • Hospital Do Cancer de Londrina
    Londrina, 86015-520, Brazil
  • Centro Gaucho Integrado de Oncologia Hospital Mae de Deus
    Porto Alegre, 90110-270, Brazil
  • Fundacao Faculdade Regional de Medicina de Sao Jose Do Rio Preto
    São José do Rio Preto, 15090-000, Brazil
  • Icesp Instituto Do Cancer Do Estado de Sao Paulo Octavio Frias de Oliveira
    São Paulo, 01246-000, Brazil
  • Cross Cancer Institute
    Edmonton, Alberta T6G 1Z2, Canada
  • The Second Hospital of Anhui Medical University
    Hefei, Anhui 230601, China
  • The Fifth Medical Center of Chinese Pla General Hospital
    Beijing, Beijing Municipality 100071, China
  • Fujian Cancer Hospital
    Fuzhou, Fujian 350014, China
  • Affiliated Hospital of Hebei University
    Baoding, Hebei 071000, China
  • Harbin Medical University Cancer Hospital
    Harbin, Heilongjiang 150000, China
  • Henan Cancer Hospital
    Zhengzhou, Henan 450000, China
  • Hubei Cancer Hospital
    Wuhan, Hubei 430079, China
  • Nantong Tumor Hospital Branch North
    Nantong, Jiangsu 226000, China
  • The First Affiliated Hospital of Soochow University
    Suzhou, Jiangsu 215006, China
  • The First Affiliated Hospital of Nanchang University Branch Xianghu
    Nanchang, Jiangxi 332000, China
  • Jining No1 Peoples Hospital East Branch
    Jining, Shandong 272002, China
  • Linyi Peoples Hospital
    Linyi, Shandong 276000, China
  • Affiliated Zhongshan Hospital of Fudan University
    Shanghai, Shanghai Municipality 200032, China
  • Shanghai East Hospital Branch Hospital
    Shanghai, Shanghai Municipality 200123, China
  • Shanghai Pulmonary Hospital
    Shanghai, Shanghai Municipality 200433, China
  • Shanxi Provincial Cancer Hospital
    Taiyuan, Shanxi 030013, China
  • Tianjin Medical University Cancer Institute and Hospital
    Tianjin, Tianjin Municipality 300060, China
  • Taizhou Hospital of Zhejiang
    Taizhou, Zhejiang 317000, China
  • Institut Curie
    Paris, 75005, France
  • Chu Nantes Hopital Nord Laennec
    SaintHerblain, 44805, France
  • Arensia Exploratory Medicine Llc
    Tbilisi, 0112, Georgia
  • Regina Elena, Istituto Nazionale Dei Tumori, Ifo, Irccs
    Roma, 00144, Italy
  • Centro Ricerche Cliniche Di Verona
    Verona, 37126, Italy
  • Pulau Pinang Hospital
    George Town, 10450, Malaysia
  • Tengku Ampuan Afzan Hospital
    Kuantan, 25100, Malaysia
  • Sarawak General Hospital
    Kuching, 93586, Malaysia
  • The Institute of Oncology, Arensia Exploratory Medicine
    Chisinau, 2025, Moldova
  • Institute of Oncology Bucharest Prof Dr Alexandru Trestioreanu
    Bucureti, 022328, Romania
  • Arensia Research Clinic At the Oncology Institute Prof Dr Ion Chiricu
    ClujNapoca, 400015, Romania
  • National Cancer Centre Singapore
    Singapore, 168583, Singapore
  • Chungbuk National University Hospital
    Cheongju-si, Chungcheongbukdo 28644, South Korea
  • National Cancer Center (Korea)
    IlsandongGu GoyangSi, Gyeonggi-do 10408, South Korea
  • The Catholic University of Korea, St Vincents Hospital
    PaldalGu SuwonSi, Gyeonggi-do 16247, South Korea
  • Seoul National University Bundang Hospital
    Seongnam-si, Gyeonggi-do 13620, South Korea
  • Samsung Medical Center
    GangnamGu, Seoul Teugbyeolsi 06351, South Korea
  • Severance Hospital Yonsei University Health System
    SeodaemunGu, Seoul Teugbyeolsi 03722, South Korea
  • Asan Medical Center
    SongpaGu, Seoul Teugbyeolsi 05505, South Korea
  • Hospital Universitario Vall Dhebron
    Barcelona, 08035, Spain
  • Hospital Universitario 12 de Octubre
    Madrid, 28041, Spain
  • Hospital Universitario Virgen Del Rocio
    Seville, 41013, Spain
  • Songklanagarind Hospital (Prince of Songkhla University)
    Hat Yai, 90110, Thailand
  • Srinagarind Hospital (Khon Kaen University)
    Muang, 40002, Thailand
  • Maharaj Nakorn Chiang Mai Hospital (Chiang Mai University)
    Muang, 50200, Thailand
  • Hrh Princess Maha Chakri Sirindhorn Medical Center (Srinakharinwirot University)
    Ongkharak, 26120, Thailand
08

References and documents

Individual participant data

Plan to share: Yes — BeiGene shares data on completed studies responsibly and provides qualified scientific and medical researchers access to data and supporting documentation for clinical trials in dossiers for medicines and indications after submission and approval in the United States, China, and Europe. Clinical trials supporting subsequent local approvals, new indications, or combination products are eligible for sharing once corresponding regulatory approvals are achieved. BeiGene shares data only when permitted by applicable data privacy and security laws and regulations, when it is feasible to do so without compromising the privacy of study participants, and other considerations. Qualified researchers with appropriate competencies who are engaged in novel scientific research may submit a request for participant-level data with a research proposal for BeiGene review. Research teams must include a biostatistician and sign a Data Sharing Agreement prior to receiving access to clinical trial data.

Supporting information: Study protocol, Statistical analysis plan, Clinical study report

Time frame: See plan description

Access criteria: See plan description

Data sharing details ↗ · beigene.com

No publications or documents are linked to this record.

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedDate before it movedWhere the date was before it movedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Feb 2023 to primary completion in Dec 2025, 34 months.

Of 317 industry-sponsored phase 2 interventional studies under Carcinoma, Non-Small-Cell Lung, half reached primary completion within 37 months of starting (the median), counting those still running; a quarter within 24 and three quarters within 59. This study's 34 months is close to that.

Counting every sponsor, half of 1,047 studies reached it within 48 months; a quarter within 30 and three quarters within 76.

Start moved once since we started tracking on Sep 25, 2026: Mar 2023 → Feb 2023, on Oct 30, 2026.

Earlier changes are on the record history on ClinicalTrials.gov ↗

How these figures are worked out, and which studies are left out of them.

Registered
Nov 23, 2022
First posted
Dec 2, 2022
StartActual
Feb 10, 2023was Mar 2023
Primary completionActual
Dec 19, 2025
CompletionActual
Oct 29, 2026
Last update
Oct 30, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Status
Active, not recruiting→Completed
changed Oct 30, 2026
Start date
Mar 7, 2023→Feb 10, 2023
Oct 30, 2026
Primary completion
Dec 31, 2025→Dec 19, 2025
Oct 30, 2026
Enrollment
400 (estimated)→418 (actual)
Oct 30, 2026
Show all 1 update
  1. Oct 30, 2026
    Active, not recruiting→Completed
    Start date Mar 7, 2023→Feb 10, 2023
    Primary completion Dec 31, 2025→Dec 19, 2025
    Enrollment 400 (estimated)→418 (actual)
    + 2 other changes: verification date and arm descriptions

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT05635708
Lead sponsor
BeiGene
Responsible party
Sponsor
First posted
Dec 2, 2022
Start date
Feb 10, 2023
Primary completion
Dec 19, 2025
Completion
Oct 29, 2026
Last update
Oct 30, 2026

Study contacts

Study Director
study director · BeiGene

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Oct 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Tislelizumab

Start the discussion